In 2006, the Boehringer Ingelheim group of companies maintained its successful course again, growing faster than the pharmaceutical market for the seventh successive year. Get an overview of the Financial Highlights 2006 and the 1st Half Results 2007.
| Amounts in millions of EUR, unless otherwise indicated |
2006 | 2005 | Change |
|---|---|---|---|
| Net sales | 10,574 | 9,535 | 11 % |
| Net sales by region | |||
| Europe | 31 % | 33 % | |
| Americas | 51 % | 48 % | |
| Asia, Australasia, Africa | 18 % | 19 % | |
| Net sales by business area | |||
| Human Pharmaceuticals | 96 % | 96 % | |
| Animal Health | 4 % | 4 % | |
| Research and Development | 1,574 | 1,360 | 16 % |
| Personnel costs | 2,836 | 2,671 | 6 % |
| Average number of employees* | 38,428 | 37,406 | 3 % |
| Operating income | 2,140 | 1,923 | 11 % |
| Operating income as % of sales | 20.2 % | 20.2 % | |
| Income after taxes | 1,729 | 1,514 | 14 % |
| Income after taxes as % of sales | 16.4 % | 15.9 % | |
| Shareholders' equity | 5,175 | 4,609 | 12 % |
| Return on shareholders' equity | 37.4 % | 34.2 % | |
| Cash Flow | 2,317 | 2,069 | 12 % |
| Investments in tangible assets | 596 | 532 | 12 % |
| Depreciation of tangible assets | 419 | 439 | -5 % |
| Boehringer Ingelheim Corporation | 1st Half 2007 | 1st Half 2006 | Change in % | Currency- adjusted in % |
|---|---|---|---|---|
| Net sales | 5,407 | 5,296 | +2.1 % | +7.5 % |
| Human Pharmaceutical Business of which |
5,212 | 5,114 | +1,9 % | +7,3 % |
| Prescription Medicines | 4,310 | 4,201 | +2.6 % | +8.4 % |
| Consumer Healthcare | 560 | 522 | +7.4 % | +12.5 % |
| Pharma Chemicals | 79 | 82 | -3.3 % | +0.9 % |
| Biopharmaceuticals | 196 | 221 | -11.5 % | -11.5 % |
| Animal Health Business | 195 | 182 | +7,3 % | +10,7 % |
| Operating Income | 1,001 | 1,033 | +3,1 % | |
| Personnel Capacity* | 38,351 | 36,945 | +3,8 % |
